The biology to repair catastrophic nerve and spinal-cord injury has been proven in the literature for two decades. What has never existed is the biomanufacturing infrastructure capable of producing it at clinical scale. Building that infrastructure is a first-in-class undertaking and the single step that unlocks an entire category of regenerative medicine.
Proven biology.
Unbuilt Manufacturing.
THE PROBLEM
The infrastructure bottleneck preventing scalable regenerative breakthroughs.
Scalable Manufacturing
Engineered tissue is currently produced by hand, one construct at a time, in a research laboratory. That process yields real biology but not a repeatable one, since batch-to-batch variability persists without a standardized, regulatory-compliant pathway to resolve it at clinical scale.
Parallel technology constraints
Non-destructive testing methods and imaging modalities capable of validating tissue quality at scale are only now maturing, compounding the manufacturing bottleneck.
Reaching patients
Without scalable, reproducible production, engineered tissue cannot advance beyond the laboratory to serve any clinically meaningful patient population.
THE ASK
A bold, necessary undertaking, and the beginning of a new category of medicine.
Building first-of-its-kind manufacturing infrastructure is a heavy lift. It is also the one investment standing between proven science and every patient who needs it. Phase 0 establishes the validated manufacturing and quality foundation required to unlock subsequent institutional investment.
THE SOLUTION
Building the missing link between biology and patients.
01Build first-of-its-kind advanced manufacturing infrastructure
02Absorb the high upfront cost so the science can be used again and again
03Standardize and automate so every batch meets clinical-grade quality
04Operate as the manufacturing partner behind additional engineered-tissue therapies as they mature
05Deploy robotics and machine learning for reproducible, continually improving production
ONE PLATFORM, MANY THERAPIES